Class Action Reminder for Mereo BioPharma Shareholders
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 18 2026
0mins
Should l Buy MREO?
Source: Globenewswire
- Lawsuit Background: Robbins LLP reminds all investors who purchased Mereo BioPharma Group plc (NASDAQ: MREO) American Depository Shares between June 5, 2023, and December 26, 2025, that a class action has been filed, alleging the company misled investors regarding clinical trial results.
- Study Failures: The complaint indicates that Mereo failed to meet the primary endpoint of reducing clinical fracture rates in its Phase 3 ORBIT and COSMIC studies, despite previously optimistic statements about the drug setrusumab, leading investors to buy shares at artificially inflated prices.
- Stock Price Plunge: Following the announcement on December 29, 2025, that the studies did not meet their endpoints, Mereo's ADS price plummeted from $2.31 on December 26, 2025, to $0.29, representing a decline of over 87.7%, severely impacting shareholder value.
- Next Steps: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 6, 2026; Robbins LLP offers contingency fee representation, ensuring shareholders can recover losses without upfront costs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MREO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MREO
Wall Street analysts forecast MREO stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.316
Low
0.50
Averages
2.08
High
5.00
Current: 0.316
Low
0.50
Averages
2.08
High
5.00
About MREO
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder for Mereo BioPharma Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Mereo BioPharma ADS between June 5, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which reduces financial barriers and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that Mereo BioPharma misled investors regarding the expected outcomes of its Phase 3 Orbit and COSMIC studies for setrusumab, leading to purchases at inflated prices and subsequent investor losses when the true results were revealed.
- Law Firm's Strength: Rosen Law Firm is recognized for its success in securities class actions, having achieved the largest settlement against a Chinese company and recovering hundreds of millions for investors, showcasing its expertise and resource capabilities in handling such cases.
See More
Reminder of Class Action Lawsuits Against Mereo BioPharma and Others
- Lawsuit Overview: Holzer & Holzer LLC reminds investors of a class action lawsuit against Mereo BioPharma Group plc (NASDAQ: MREO) for failing to disclose material facts regarding setrusumab from June 2023 to December 2025, with a deadline of April 6, 2026, for investors to apply as lead plaintiffs if they suffered significant losses.
- Pomdoctor Case: The class action against Pomdoctor Limited (NASDAQ: POM) alleges fraudulent stock promotion through social media misinformation between October 2025 and December 2025, with a similar deadline of April 6, 2026, for affected investors to seek lead plaintiff status.
- Ultragenyx Lawsuit: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) faces a class action lawsuit for not disclosing expected results of its Phase III Orbit and Cosmic studies from August 2023 to December 2025, urging impacted investors to act by April 6, 2026.
- Legal Services Background: Holzer & Holzer LLC, recognized as a top-rated securities litigation firm, has been dedicated to representing shareholders since 2000, recovering hundreds of millions for victims of corporate misconduct, highlighting its expertise and influence in the securities litigation field.
See More
Mereo BioPharma Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors that Mereo BioPharma Group plc is facing a class action lawsuit for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 5, 2023, and December 26, 2025.
- False Statements Exposed: The complaint alleges that Mereo concealed negative facts about its Phase 3 ORBIT and COSMIC programs, rendering its public statements false and materially misleading throughout the class period.
- Investor Losses: When the market learned that neither program hit its primary endpoint, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could impact its stock price and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected shareholders to contact them before April 6, 2026, to participate in the lawsuit and discuss their rights, demonstrating a commitment to protecting investor interests.
See More
Class Action Lawsuit Reminder Against Mereo BioPharma Group plc
- Lawsuit Background: DJS Law Group reminds investors of a class action lawsuit against Mereo BioPharma Group plc for violations of §§10(b) and 20(a) of the Securities Exchange Act, covering stock transactions from June 5, 2023, to December 26, 2025.
- False Statements: The complaint alleges that Mereo made false and misleading statements regarding its Phase 3 ORBIT and COSMIC programs, which failed to meet endpoints against placebo or bisphosphonate control groups, misleading investors throughout the class period.
- Investor Losses: Affected shareholders are encouraged to contact DJS Law Group to participate in potential lead plaintiff appointments, emphasizing that one does not need to be a lead plaintiff to partake in recovery, thus providing an opportunity for investors to recover losses.
- Legal Expertise: DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through balanced counseling and aggressive advocacy, serving some of the largest hedge funds and alternative asset managers globally.
See More
Faruqi & Faruqi Investigates Mereo BioPharma for Investor Losses
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating Mereo BioPharma, focusing on potential claims from investors who purchased or acquired securities between June 5, 2023, and December 26, 2025, indicating possible legal risks for the company.
- Investor Rights Reminder: The firm reminds investors that April 6, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect legal rights.
- Contact Information Provided: Investors who suffered losses are encouraged to contact Faruqi & Faruqi partner Josh Wilson directly, with multiple contact options provided to facilitate investor inquiries, reflecting the firm's commitment to client service.
- Potential Impact Assessment: This investigation may negatively affect Mereo BioPharma's stock price and market confidence, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
See More
Class Action Filed Against Mereo BioPharma Group plc for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Mereo BioPharma Group plc, aiming to recover damages for investors who purchased securities between June 5, 2023, and December 26, 2025, highlighting significant investor concerns regarding the company's financial transparency.
- Allegations of False Statements: The complaint alleges that Mereo provided overly optimistic statements to investors while concealing significant adverse facts related to the Phase 3 ORBIT and COSMIC programs, leading to investor misunderstandings about the company's prospects and impacting investment decisions.
- Clinical Trial Failures: The lawsuit points out that Mereo's two critical clinical trials failed to meet primary endpoints, failing to effectively reduce annualized clinical fracture rates compared to placebo or bisphosphonate control groups, which could severely impact the company's future market performance.
- Investor Rights Protection: Investors are encouraged to apply to be lead plaintiffs by April 6, 2026, indicating that the legal team will provide risk-free legal support for investors, emphasizing the importance of protecting investor rights and interests.
See More
Reminder for Mereo BioPharma Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Mereo BioPharma ADS between June 5, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which reduces financial barriers and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that Mereo BioPharma misled investors regarding the expected outcomes of its Phase 3 Orbit and COSMIC studies for setrusumab, leading to purchases at inflated prices and subsequent investor losses when the true results were revealed.
- Law Firm's Strength: Rosen Law Firm is recognized for its success in securities class actions, having achieved the largest settlement against a Chinese company and recovering hundreds of millions for investors, showcasing its expertise and resource capabilities in handling such cases.
See More
Reminder of Class Action Lawsuits Against Mereo BioPharma and Others
- Lawsuit Overview: Holzer & Holzer LLC reminds investors of a class action lawsuit against Mereo BioPharma Group plc (NASDAQ: MREO) for failing to disclose material facts regarding setrusumab from June 2023 to December 2025, with a deadline of April 6, 2026, for investors to apply as lead plaintiffs if they suffered significant losses.
- Pomdoctor Case: The class action against Pomdoctor Limited (NASDAQ: POM) alleges fraudulent stock promotion through social media misinformation between October 2025 and December 2025, with a similar deadline of April 6, 2026, for affected investors to seek lead plaintiff status.
- Ultragenyx Lawsuit: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) faces a class action lawsuit for not disclosing expected results of its Phase III Orbit and Cosmic studies from August 2023 to December 2025, urging impacted investors to act by April 6, 2026.
- Legal Services Background: Holzer & Holzer LLC, recognized as a top-rated securities litigation firm, has been dedicated to representing shareholders since 2000, recovering hundreds of millions for victims of corporate misconduct, highlighting its expertise and influence in the securities litigation field.
See More
Mereo BioPharma Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors that Mereo BioPharma Group plc is facing a class action lawsuit for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 5, 2023, and December 26, 2025.
- False Statements Exposed: The complaint alleges that Mereo concealed negative facts about its Phase 3 ORBIT and COSMIC programs, rendering its public statements false and materially misleading throughout the class period.
- Investor Losses: When the market learned that neither program hit its primary endpoint, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could impact its stock price and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected shareholders to contact them before April 6, 2026, to participate in the lawsuit and discuss their rights, demonstrating a commitment to protecting investor interests.
See More
Class Action Lawsuit Reminder Against Mereo BioPharma Group plc
- Lawsuit Background: DJS Law Group reminds investors of a class action lawsuit against Mereo BioPharma Group plc for violations of §§10(b) and 20(a) of the Securities Exchange Act, covering stock transactions from June 5, 2023, to December 26, 2025.
- False Statements: The complaint alleges that Mereo made false and misleading statements regarding its Phase 3 ORBIT and COSMIC programs, which failed to meet endpoints against placebo or bisphosphonate control groups, misleading investors throughout the class period.
- Investor Losses: Affected shareholders are encouraged to contact DJS Law Group to participate in potential lead plaintiff appointments, emphasizing that one does not need to be a lead plaintiff to partake in recovery, thus providing an opportunity for investors to recover losses.
- Legal Expertise: DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through balanced counseling and aggressive advocacy, serving some of the largest hedge funds and alternative asset managers globally.
See More
Faruqi & Faruqi Investigates Mereo BioPharma for Investor Losses
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating Mereo BioPharma, focusing on potential claims from investors who purchased or acquired securities between June 5, 2023, and December 26, 2025, indicating possible legal risks for the company.
- Investor Rights Reminder: The firm reminds investors that April 6, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect legal rights.
- Contact Information Provided: Investors who suffered losses are encouraged to contact Faruqi & Faruqi partner Josh Wilson directly, with multiple contact options provided to facilitate investor inquiries, reflecting the firm's commitment to client service.
- Potential Impact Assessment: This investigation may negatively affect Mereo BioPharma's stock price and market confidence, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
See More
Class Action Filed Against Mereo BioPharma Group plc for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Mereo BioPharma Group plc, aiming to recover damages for investors who purchased securities between June 5, 2023, and December 26, 2025, highlighting significant investor concerns regarding the company's financial transparency.
- Allegations of False Statements: The complaint alleges that Mereo provided overly optimistic statements to investors while concealing significant adverse facts related to the Phase 3 ORBIT and COSMIC programs, leading to investor misunderstandings about the company's prospects and impacting investment decisions.
- Clinical Trial Failures: The lawsuit points out that Mereo's two critical clinical trials failed to meet primary endpoints, failing to effectively reduce annualized clinical fracture rates compared to placebo or bisphosphonate control groups, which could severely impact the company's future market performance.
- Investor Rights Protection: Investors are encouraged to apply to be lead plaintiffs by April 6, 2026, indicating that the legal team will provide risk-free legal support for investors, emphasizing the importance of protecting investor rights and interests.
See More
